Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.54 |
| ▸ | CNR2 | P34972 | 12/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440433 | 0.84 | CNR1 (0.69) | CNR1CNR2P2RX7KDM4EMAPT | |
| SCHEMBL5162184 | 0.83 | CNR1 (0.73) | CNR1CNR2CYP2C9 | |
| SCHEMBL5161954 | 0.82 | CNR1 (0.77) | CNR1CNR2CYP2C9 | |
| SCHEMBL5234293 | 0.79 | CNR1 (0.61) | CNR1CNR2CYP2C9KDM4EMAPT | |
| SCHEMBL5239258 | 0.79 | CNR1 (0.54) | CNR1CNR2KDM4EMAPT | |
| SCHEMBL5239126 | 0.78 | CNR1 (0.72) | CNR1CNR2CYP2C9 | |
| SCHEMBL5270671 | 0.78 | CNR1 (0.58) | CNR1CNR2CYP2C9 | |
| SCHEMBL5236167 | 0.77 | CNR1 (0.57) | CNR1CNR2CYP2C9 | |
| SCHEMBL5236335 | 0.77 | CNR1 (0.60) | CNR1CNR2CYP2C9 | |
| SCHEMBL5240699 | 0.75 | CNR1 (0.70) | CNR1CNR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | claimed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CNR1 6/4885CNR2 11/4885BRD4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.